Aridis Pharmaceuticals Operating Income

Aridis Pharmaceuticals (ARDS) currently reports a operating income of $-880K as of September 2023. That compares with $-33M in the prior-year period — up 97.3% year over year. Use the charts on this page to explore Aridis Pharmaceuticals's operating income history and peer comparisons.

Aridis Pharmaceuticals's operating income increased from $-33M to $-880K — a 97.3% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aridis Pharmaceuticals reported $-880K in operating income as of September 2023. That compares with $-33M in the prior-year period — up 97.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-880K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Aridis Pharmaceuticals, and consider following ARDS for alerts when major investors trade the stock.

Aridis Pharmaceuticals is classified in the Healthcare sector. On operating income, it currently shows $-880K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ARDS with unrelated industries.